Ultra-sensitive ctDNA monitoring predicts ICI response in melanoma [Video]

Christoffer Gebhardt, MD, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, discusses findings from a retrospective study, which analyzed plasma samples from patients with advanced metastatic melanoma undergoing immune checkpoint inhibitor (ICI) treatment, such as nivolumab and ipilimumab. An increase in early circulating tumor DNA (ctDNA) predicted progression-free survival (PFS), while ctDNA clearance correlated with complete responses (CR). Molecular progression was a significant predictor of overall survival (OS), emphasizing the utility of ultra-sensitive ctDNA monitoring in late-stage melanoma for predicting ICI response. This interview took place at American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.